Protagonist Therapeutics Hits New 52-Week High of $63.30

Protagonist Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 63.30 on September 19, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,496 million.
Over the past year, Protagonist Therapeutics has demonstrated impressive growth, with a performance increase of 87.52%, significantly outpacing the S&P 500's 16.64% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 60.00, reflecting its valuation in the market. Additionally, Protagonist Therapeutics maintains a return on equity of 7.79%, indicating effective management of shareholder equity.

Despite not offering dividends, the company’s financial metrics, including a price-to-book ratio of 5.23 and a debt-to-equity ratio of -0.85, provide insight into its financial health and capital structure. The stock's previous 52-week low was recorded at USD 33.31, highlighting the significant upward movement in its price.